Trials / Completed
CompletedNCT05163834
Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
A Randomized, Open-label, Placebo-Controlled, Parallel-Group Study to Evaluate the Immune Response to the Polyvalent Pneumococcal Vaccine (PNEUMOVAX 23) in Healthy Participants Receiving Intravenous Efgartigimod or Placebo
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, open-label, placebo-controlled phase 1 study in healthy adult volunteers to provide information regarding vaccination with a common pneumococcal polysaccharide vaccine while receiving efgartigimod.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Efgartigimod | intravenous infusion of efgartigimod |
| OTHER | Placebo | intravenous infusion of placebo |
| BIOLOGICAL | PNEUMOVAX 23 | PNEUMOVAX 23 vaccine |
Timeline
- Start date
- 2021-11-17
- Primary completion
- 2022-03-08
- Completion
- 2022-03-08
- First posted
- 2021-12-20
- Last updated
- 2022-03-17
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05163834. Inclusion in this directory is not an endorsement.